Autológ csontveloi eredetu ossejtterápia eredmńye elorehaladott perifériás artériás érbetegségben

Translated title of the contribution: A pilot study with autologous bone marrow-derived stem cell therapy in patients with severe peripheral arterial disorder

Zoltán Boda, Miklós Udvardy, Katalin Farkas, Judit Tóth, László Jámbor, Pál Soltész, K. Katalin Rázsó, Zsolt Oláh, Péter Ilonczai, Mariann Szarvas, Krisztina Litauszky, János Hunyadi, Tamás Sipos, János Kappelmayer, Zoltán Veréb, Éva Rajnavölgyi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background and aims: Amputation is the only current option for relief of rest pain or gangrena in patients with severe peripheral arterial disease. Up to now, no effective blood-flow enhancement therapies are available. Autologous bone marrow-derived stem cell transplantation is an arising therapy modality with an option of building new blood vessels through endothelial stem and/or progenitor cells. Patients and methods: Five patients with severe peripheral arterial disorder were treated by autologous bone marrow-derived stem cell therapy. CD34+, CD133+ and CD45± cell number and ratio were determined. CD34+ cells were isolated by magnetic separation and collected into a 10 ml sample. The cell suspension was administered by local intramuscular injections (0.5-1.0 ml injections in the musculus gastrocnemius). The follow-up (before; 1, 3, 6, 9 and 12 months after the autologous bone marrow-derived stem cell therapy) based on clinical (rest pain, walking distance without pain, changes of non-healing ischaemic ulcers, ankle-brachial index) and laboratory (angiography, Color- and Laser-Doppler scan, measurement of transcutaneous oxygen tension and endothel function test) parameters was documented and analyzed. Results: Improvement of pain and walking distance was observed in all five cases. In three cases the non-healing ischaemic ulcers disappeared, in one other case they became smaller and thinner, and in one case no change was realized. The average of ankle-brachial index improved significantly (before: 0.41, twelve months after: 0.83). New collaterals were detected by angiography in three patients, but duplex ultrasonography detected improvement in one patient only. Before and 1, 6 and 12 months after stem cell therapy the transcutaneous oxygen tension changed on the foot from 18.80/16.78/23.83/37.50 mmHg, and on the calf from 36.66/31.25/45.00/37.30 mmHg. The macro- and microcirculation parameters did not show improvement after 1 month, however, after 3, 6, 9 and 12 months improved parameters were recorded. Severe adverse events were not observed. In one case elevated level of serum creatinin phosphokinase, and in another case a mild form of vasculitis were detected. Conclusion: Autologous bone marrow-derived stem cell therapy with isolated CD34+ cells is effective, safe and results in sustained clinical benefit for patients with severe peripheral arterial disease.

Original languageHungarian
Pages (from-to)531-540
Number of pages10
JournalOrvosi Hetilap
Volume149
Issue number12
DOIs
Publication statusPublished - Mar 23 2008

Fingerprint

Cell- and Tissue-Based Therapy
Stem Cells
Bone Marrow
Pain
Ankle Brachial Index
Peripheral Arterial Disease
Ulcer
Walking
Angiography
Oxygen
Intramuscular Injections
Stem Cell Transplantation
Microcirculation
Vasculitis
Amputation
Blood Vessels
Foot
Ultrasonography
Suspensions
Lasers

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Autológ csontveloi eredetu ossejtterápia eredmńye elorehaladott perifériás artériás érbetegségben. / Boda, Zoltán; Udvardy, Miklós; Farkas, Katalin; Tóth, Judit; Jámbor, László; Soltész, Pál; Rázsó, K. Katalin; Oláh, Zsolt; Ilonczai, Péter; Szarvas, Mariann; Litauszky, Krisztina; Hunyadi, János; Sipos, Tamás; Kappelmayer, János; Veréb, Zoltán; Rajnavölgyi, Éva.

In: Orvosi Hetilap, Vol. 149, No. 12, 23.03.2008, p. 531-540.

Research output: Contribution to journalArticle

Boda, Z, Udvardy, M, Farkas, K, Tóth, J, Jámbor, L, Soltész, P, Rázsó, KK, Oláh, Z, Ilonczai, P, Szarvas, M, Litauszky, K, Hunyadi, J, Sipos, T, Kappelmayer, J, Veréb, Z & Rajnavölgyi, É 2008, 'Autológ csontveloi eredetu ossejtterápia eredmńye elorehaladott perifériás artériás érbetegségben', Orvosi Hetilap, vol. 149, no. 12, pp. 531-540. https://doi.org/10.1556/OH.2008.28125
Boda, Zoltán ; Udvardy, Miklós ; Farkas, Katalin ; Tóth, Judit ; Jámbor, László ; Soltész, Pál ; Rázsó, K. Katalin ; Oláh, Zsolt ; Ilonczai, Péter ; Szarvas, Mariann ; Litauszky, Krisztina ; Hunyadi, János ; Sipos, Tamás ; Kappelmayer, János ; Veréb, Zoltán ; Rajnavölgyi, Éva. / Autológ csontveloi eredetu ossejtterápia eredmńye elorehaladott perifériás artériás érbetegségben. In: Orvosi Hetilap. 2008 ; Vol. 149, No. 12. pp. 531-540.
@article{5f1fc4b1e0274efa9dd693cd22c46bba,
title = "Autol{\'o}g csontveloi eredetu ossejtter{\'a}pia eredmńye elorehaladott perif{\'e}ri{\'a}s art{\'e}ri{\'a}s {\'e}rbetegs{\'e}gben",
abstract = "Background and aims: Amputation is the only current option for relief of rest pain or gangrena in patients with severe peripheral arterial disease. Up to now, no effective blood-flow enhancement therapies are available. Autologous bone marrow-derived stem cell transplantation is an arising therapy modality with an option of building new blood vessels through endothelial stem and/or progenitor cells. Patients and methods: Five patients with severe peripheral arterial disorder were treated by autologous bone marrow-derived stem cell therapy. CD34+, CD133+ and CD45± cell number and ratio were determined. CD34+ cells were isolated by magnetic separation and collected into a 10 ml sample. The cell suspension was administered by local intramuscular injections (0.5-1.0 ml injections in the musculus gastrocnemius). The follow-up (before; 1, 3, 6, 9 and 12 months after the autologous bone marrow-derived stem cell therapy) based on clinical (rest pain, walking distance without pain, changes of non-healing ischaemic ulcers, ankle-brachial index) and laboratory (angiography, Color- and Laser-Doppler scan, measurement of transcutaneous oxygen tension and endothel function test) parameters was documented and analyzed. Results: Improvement of pain and walking distance was observed in all five cases. In three cases the non-healing ischaemic ulcers disappeared, in one other case they became smaller and thinner, and in one case no change was realized. The average of ankle-brachial index improved significantly (before: 0.41, twelve months after: 0.83). New collaterals were detected by angiography in three patients, but duplex ultrasonography detected improvement in one patient only. Before and 1, 6 and 12 months after stem cell therapy the transcutaneous oxygen tension changed on the foot from 18.80/16.78/23.83/37.50 mmHg, and on the calf from 36.66/31.25/45.00/37.30 mmHg. The macro- and microcirculation parameters did not show improvement after 1 month, however, after 3, 6, 9 and 12 months improved parameters were recorded. Severe adverse events were not observed. In one case elevated level of serum creatinin phosphokinase, and in another case a mild form of vasculitis were detected. Conclusion: Autologous bone marrow-derived stem cell therapy with isolated CD34+ cells is effective, safe and results in sustained clinical benefit for patients with severe peripheral arterial disease.",
keywords = "Severe peripheral arterial disorder, Stem cell therapy",
author = "Zolt{\'a}n Boda and Mikl{\'o}s Udvardy and Katalin Farkas and Judit T{\'o}th and L{\'a}szl{\'o} J{\'a}mbor and P{\'a}l Solt{\'e}sz and R{\'a}zs{\'o}, {K. Katalin} and Zsolt Ol{\'a}h and P{\'e}ter Ilonczai and Mariann Szarvas and Krisztina Litauszky and J{\'a}nos Hunyadi and Tam{\'a}s Sipos and J{\'a}nos Kappelmayer and Zolt{\'a}n Ver{\'e}b and {\'E}va Rajnav{\"o}lgyi",
year = "2008",
month = "3",
day = "23",
doi = "10.1556/OH.2008.28125",
language = "Hungarian",
volume = "149",
pages = "531--540",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "12",

}

TY - JOUR

T1 - Autológ csontveloi eredetu ossejtterápia eredmńye elorehaladott perifériás artériás érbetegségben

AU - Boda, Zoltán

AU - Udvardy, Miklós

AU - Farkas, Katalin

AU - Tóth, Judit

AU - Jámbor, László

AU - Soltész, Pál

AU - Rázsó, K. Katalin

AU - Oláh, Zsolt

AU - Ilonczai, Péter

AU - Szarvas, Mariann

AU - Litauszky, Krisztina

AU - Hunyadi, János

AU - Sipos, Tamás

AU - Kappelmayer, János

AU - Veréb, Zoltán

AU - Rajnavölgyi, Éva

PY - 2008/3/23

Y1 - 2008/3/23

N2 - Background and aims: Amputation is the only current option for relief of rest pain or gangrena in patients with severe peripheral arterial disease. Up to now, no effective blood-flow enhancement therapies are available. Autologous bone marrow-derived stem cell transplantation is an arising therapy modality with an option of building new blood vessels through endothelial stem and/or progenitor cells. Patients and methods: Five patients with severe peripheral arterial disorder were treated by autologous bone marrow-derived stem cell therapy. CD34+, CD133+ and CD45± cell number and ratio were determined. CD34+ cells were isolated by magnetic separation and collected into a 10 ml sample. The cell suspension was administered by local intramuscular injections (0.5-1.0 ml injections in the musculus gastrocnemius). The follow-up (before; 1, 3, 6, 9 and 12 months after the autologous bone marrow-derived stem cell therapy) based on clinical (rest pain, walking distance without pain, changes of non-healing ischaemic ulcers, ankle-brachial index) and laboratory (angiography, Color- and Laser-Doppler scan, measurement of transcutaneous oxygen tension and endothel function test) parameters was documented and analyzed. Results: Improvement of pain and walking distance was observed in all five cases. In three cases the non-healing ischaemic ulcers disappeared, in one other case they became smaller and thinner, and in one case no change was realized. The average of ankle-brachial index improved significantly (before: 0.41, twelve months after: 0.83). New collaterals were detected by angiography in three patients, but duplex ultrasonography detected improvement in one patient only. Before and 1, 6 and 12 months after stem cell therapy the transcutaneous oxygen tension changed on the foot from 18.80/16.78/23.83/37.50 mmHg, and on the calf from 36.66/31.25/45.00/37.30 mmHg. The macro- and microcirculation parameters did not show improvement after 1 month, however, after 3, 6, 9 and 12 months improved parameters were recorded. Severe adverse events were not observed. In one case elevated level of serum creatinin phosphokinase, and in another case a mild form of vasculitis were detected. Conclusion: Autologous bone marrow-derived stem cell therapy with isolated CD34+ cells is effective, safe and results in sustained clinical benefit for patients with severe peripheral arterial disease.

AB - Background and aims: Amputation is the only current option for relief of rest pain or gangrena in patients with severe peripheral arterial disease. Up to now, no effective blood-flow enhancement therapies are available. Autologous bone marrow-derived stem cell transplantation is an arising therapy modality with an option of building new blood vessels through endothelial stem and/or progenitor cells. Patients and methods: Five patients with severe peripheral arterial disorder were treated by autologous bone marrow-derived stem cell therapy. CD34+, CD133+ and CD45± cell number and ratio were determined. CD34+ cells were isolated by magnetic separation and collected into a 10 ml sample. The cell suspension was administered by local intramuscular injections (0.5-1.0 ml injections in the musculus gastrocnemius). The follow-up (before; 1, 3, 6, 9 and 12 months after the autologous bone marrow-derived stem cell therapy) based on clinical (rest pain, walking distance without pain, changes of non-healing ischaemic ulcers, ankle-brachial index) and laboratory (angiography, Color- and Laser-Doppler scan, measurement of transcutaneous oxygen tension and endothel function test) parameters was documented and analyzed. Results: Improvement of pain and walking distance was observed in all five cases. In three cases the non-healing ischaemic ulcers disappeared, in one other case they became smaller and thinner, and in one case no change was realized. The average of ankle-brachial index improved significantly (before: 0.41, twelve months after: 0.83). New collaterals were detected by angiography in three patients, but duplex ultrasonography detected improvement in one patient only. Before and 1, 6 and 12 months after stem cell therapy the transcutaneous oxygen tension changed on the foot from 18.80/16.78/23.83/37.50 mmHg, and on the calf from 36.66/31.25/45.00/37.30 mmHg. The macro- and microcirculation parameters did not show improvement after 1 month, however, after 3, 6, 9 and 12 months improved parameters were recorded. Severe adverse events were not observed. In one case elevated level of serum creatinin phosphokinase, and in another case a mild form of vasculitis were detected. Conclusion: Autologous bone marrow-derived stem cell therapy with isolated CD34+ cells is effective, safe and results in sustained clinical benefit for patients with severe peripheral arterial disease.

KW - Severe peripheral arterial disorder

KW - Stem cell therapy

UR - http://www.scopus.com/inward/record.url?scp=42049092640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049092640&partnerID=8YFLogxK

U2 - 10.1556/OH.2008.28125

DO - 10.1556/OH.2008.28125

M3 - Article

C2 - 18343769

AN - SCOPUS:42049092640

VL - 149

SP - 531

EP - 540

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 12

ER -